drugset / Trial / NCT00328965

Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea

NCT00328965

Phase 4 Completed GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study was designed to evaluate the anti-hypertensive efficacy of lacidipine in hypertensives with Type 2 diabetes and effectiveness on endothelial cell function in Korean population.

Timeline

Start
2004-11
Primary completion
2006-05
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacidipine Small molecule 6 mg